|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai MJ, Chang WA, Huang MS and Kuo PL:
Tumor microenvironment: A new treatment target for cancer. ISRN
Biochem. 2014:3519592014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hsu YL, Huang MS, Cheng DE, Hung JY, Yang
CJ, Chou SH and Kuo PL: Lung tumor-associated dendritic
cell-derived amphiregulin increased cancer progression. J Immunol.
187:1733–1744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuo CH, Chen KF, Chou SH, Huang YF, Wu CY,
Cheng DE, Chen YW, Yang CJ, Hung JY and Huang MS: Lung
tumor-associated dendritic cell-derived resistin promoted cancer
progression by increasing Wolf-Hirschhorn syndrome candidate
1/Twist pathway. Carcinogenesis. 34:2600–2609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuo PL, Huang MS, Hung JY, Chou SH, Chiang
SY, Huang YF, Yang CJ, Tsai MJ, Chang WA and Hsu YL: Synergistic
effect of lung tumor-associated dendritic cell-derived HB-EGF and
CXCL5 on cancer progression. Int J Cancer. 135:96–108. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alexandrov K, Rojas M and Satarug S: The
critical DNA damage by benzo(a)pyrene in lung tissues of smokers
and approaches to preventing its formation. Toxicol Lett.
198:63–68. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zuo J, Brewer DS, Arlt VM, Cooper CS and
Phillips DH: Benzo pyrene-induced DNA adducts and gene expression
profiles in target and non-target organs for carcinogenesis in
mice. BMC Genomics. 15:8802014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Zhai W, Wang H, Xia X and Zhang C:
Benzo(a)pyrene promotes A549 cell migration and invasion through
up-regulating Twist. Arch Toxicol. 89:451–458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mattivi F, Guzzon R, Vrhovsek U, Stefanini
M and Velasco R: Metabolite profiling of grape: Flavonols and
anthocyanins. J Agric Food Chem. 54:7692–7702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kozłowska A and Szostak-Wegierek D:
Flavonoids - food sources and health benefits. Rocz Panstw Zakl
Hig. 65:79–85. 2014.PubMed/NCBI
|
|
11
|
Wang CZ, Calway TD, Wen XD, Smith J, Yu C,
Wang Y, Mehendale SR and Yuan CS: Hydrophobic flavonoids from
Scutellaria baicalensis induce colorectal cancer cell apoptosis
through a mitochondrial-mediated pathway. Int J Oncol.
42:1018–1026. 2013.PubMed/NCBI
|
|
12
|
Tsui KC, Chiang TH, Wang JS, Lin LJ, Chao
WC, Chen BH and Lu JF: Flavonoids from Gynostemma pentaphyllum
exhibit differential induction of cell cycle arrest in H460 and
A549 cancer cells. Molecules. 19:17663–17681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Castillo-Muñoz N, Gómez-Alonso S,
García-Romero E and Hermosín-Gutiérrez I: Flavonol profiles of
Vitis vinifera red grapes and their single-cultivar wines. J Agric
Food Chem. 55:992–1002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
NCI-Navy Medical Oncology Branch cell line
supplement. J Cell Biochem. (Suppl)24:1–291. 1996.
|
|
15
|
Naoki K, Chen TH, Richards WG, Sugarbaker
DJ and Meyerson M: Missense mutations of the BRAF gene in human
lung adenocarcinoma. Cancer Res. 62:7001–7003. 2002.PubMed/NCBI
|
|
16
|
Koivunen JP, Kim J, Lee J, et al:
Mutations in the LKB1 tumour suppressor are frequently detected in
tumours from Caucasian but not Asian lung cancer patients. Br J
Cancer. 99:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jala VR, Radde BN, Haribabu B and Klinge
CM: Enhanced expression of G-protein coupled estrogen receptor
(GPER/GPR30) in lung cancer. BMC Cancer. 12:6242012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sunaga N, Kaira K, Imai H, et al:
Oncogenic KRAS-induced epiregulin overexpression contributes to
aggressive phenotype and is a promising therapeutic target in
non-small-cell lung cancer. Oncogene. 32:4034–4042. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou BB, Peyton M, He B, et al: Targeting
ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in
non-small cell lung cancer. Cancer Cell. 10:39–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tomshine JC, Severson SR, Wigle DA, Sun Z,
Beleford DA, Shridhar V and Horazdovsky BF: Cell proliferation and
epidermal growth factor signaling in non-small cell lung
adenocarcinoma cell lines are dependent on Rin1. J Biol Chem.
284:26331–26339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zito CR, Jilaveanu LB, Anagnostou V, et
al: Multi-level targeting of the phosphatidylinositol-3-kinase
pathway in non-small cell lung cancer cells. PLoS One.
7:e313312012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khode R, Larsen DA, Culbreath BC, et al:
Comparative study of epidermal growth factor receptor mutation
analysis on cytology smears and surgical pathology specimens from
primary and metastatic lung carcinomas. Cancer Cytopathol.
121:361–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uchiyama M, Usami N, Kondo M, et al: Loss
of heterozygosity of chromosome 12p does not correlate with KRAS
mutation in non-small cell lung cancer. Int J Cancer. 107:962–969.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Futreal PA, Wooster R and Stratton MR:
Somatic mutations in human cancer: Insights from resequencing the
protein kinase gene family. Cold Spring Harb Symp Quant Biol.
70:43–49. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Medina PP, Romero OA, Kohno T, et al:
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer
cell lines. Hum Mutat. 29:617–622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shibata T, Hanada S, Kokubu A, et al: Gene
expression profiling of epidermal growth factor receptor/KRAS
pathway activation in lung adenocarcinoma. Cancer Sci. 98:985–991.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sharma R, Haque AK, Awasthi S, Singh SV,
Piper JT and Awasthi YC: Differential carcinogenicity of
benzo[a]pyrene in male and female CD-1 mouse lung. J Toxicol
Environ Health. 52:45–62. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paik PK, Arcila ME, Fara M, et al:
Clinical characteristics of patients with lung adenocarcinomas
harboring BRAF mutations. J Clin Oncol. 29:2046–2051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ji H, Wang Z, Perera SA, et al: Mutations
in BRAF and KRAS converge on activation of the mitogen-activated
protein kinase pathway in lung cancer mouse models. Cancer Res.
67:4933–4939. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang X, Shigematsu H, Bekele BN, Roth JA,
Minna JD, Hong WK, Gazdar AF and Wistuba II: EGFR tyrosine kinase
domain mutations are detected in histologically normal respiratory
epithelium in lung cancer patients. Cancer Res. 65:7568–7572.
2005.PubMed/NCBI
|
|
33
|
Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang
Y, Li H, Ye T, Zhang Y, Luo X, et al: Oncogenic mutations are
associated with histological subtypes but do not have an
independent prognostic value in lung adenocarcinoma. Onco Targets
Ther. 7:1423–1437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bonanno L, Schiavon M, Nardo G, Bertorelle
R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F and
Favaretto A: Prognostic and predictive implications of EGFR
mutations, EGFR copy number and KRAS mutations in advanced stage
lung adenocarcinoma. Anticancer Res. 30:5121–5128. 2010.PubMed/NCBI
|
|
35
|
Marchetti A, Felicioni L, Malatesta S, et
al: Clinical features and outcome of patients with non-small-cell
lung cancer harboring BRAF mutations. J Clin Oncol. 29:3574–3579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Froudarakis ME: Pleural effusion in lung
cancer: more questions than answers. Respiration. 83:367–376. 2012.
View Article : Google Scholar : PubMed/NCBI
|
